Here’s a bold statement: Oscar Health’s latest earnings report might just flip the script on how investors view this healthcare disruptor. But here’s where it gets controversial—despite reporting a staggering net loss of $137.45 million in the third quarter of 2025 (compared to $54.6 million the previous year), the company has doubled down on its full-year guidance, projecting revenue between $12.0 billion and $12.2 billion. And this is the part most people miss—while losses per share have worsened from $0.22 to $0.53, Oscar Health’s long-term strategy hinges on technology-driven margin improvement and disciplined pricing. So, is this a red flag or a buying opportunity?
Let’s break it down. For the first nine months of 2025, Oscar Health swung from a net income of $178.98 million in 2024 to a net loss of $90.54 million. That’s a dramatic shift, but the company remains confident in its ability to recover margins through aggressive repricing and cost control. The real question is: Can they pull it off amid volatile claims trends and rapid membership growth?
Here’s the kicker: Oscar Health’s 2026 Open Enrollment plans include tech-powered health offerings like the HelloMeno menopause support plan, aimed at expanding its geographic reach and revenue streams. But—and this is crucial—these initiatives come with higher upfront administrative and claims expenses. If managed poorly, this could delay profitability. If executed well, it could be a game-changer. What do you think—is this a risky gamble or a calculated move?
Looking ahead, Oscar Health forecasts $12.4 billion in revenue and $245.4 million in earnings by 2028, based on a 4.9% annual revenue growth rate. But here’s the catch: analysts estimate a fair value of $12.38 per share, a 30% downside to its current price. Controversial interpretation alert: Could the market be overvaluing Oscar Health’s potential?
Meanwhile, Simply Wall St Community members paint a mixed picture, valuing the stock anywhere from $11.52 to $66 per share. With such a wide range, it’s clear that opinions are divided. Thought-provoking question: Are you bullish or bearish on Oscar Health’s future? Let us know in the comments!
If you’re ready to dive deeper, consider building your own investment narrative. Extraordinary returns rarely come from following the herd. Start with our free Oscar Health research report, which includes a visual Snowflake analysis to assess the company’s financial health at a glance. Or, explore other opportunities like AI-driven healthcare stocks under $10 billion in market cap—the next big thing might be hiding in plain sight.
Final food for thought: Is Oscar Health’s widening loss a temporary setback or a sign of deeper challenges? Share your take below!
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.
